← All trials
NCT03021499
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2017
- Primary completion
- Dec 1, 2019
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 324
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Aurinia Pharmaceuticals Inc.Lead sponsor
- University of North Carolina at Chapel HillOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.